Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
One pathway involves alcohol dehydrogenase, particularly the IB (class I), beta polypeptide (ADH1B, EC 1.1.1.1) enzyme. The reaction uses NAD+ to convert the ethanol into acetaldehyde (a toxic carcinogen). The enzyme acetaldehyde dehydrogenase (aldehyde dehydrogenase 2 family ALDH2, EC 1.2.1.3) then converts the acetaldehyde into the non-toxic acetate ion (commonly found in acetic acid or vinegar). This ion is in turn is broken down into carbon dioxide and water. Specifically, acetate combines with coenzyme A (acetyl-CoA synthetase) to form acetyl-CoA, via the enzymes acyl-CoA synthetase short-chain family member 2 ACSS2 (EC 6.2.1.1) and acetyl-CoA synthase 2 (ACSS1). acetyl-CoA then participates in the citric acid cycle. At even low physiological concentrations, ethanol completely saturates alcohol dehydrogenase. This is because ethanol has high affinity for the enzyme and very high concentrations of ethanol occur when it is used as a recreational substance. The microsomal ethanol-oxidizing system (MEOS), specifically mediated by the cytochrome P450 enzyme CYP2E1, is another major route of ethanol metabolism. CYP2E1 is predominantly active at higher concentrations. Repeated or chronic use of ethanol increases the activity of CYP2E1. The activity of ADH and CYP2E1 alone does not appear sufficient to fully explain the increase in ethanol metabolism rate. There may be one or more additional pathways that metabolize as much as 25 to 35% of ethanol at typical concentrations. A small amount of ethanol undergoes conjugation to form ethyl glucuronide and ethyl sulfate.
Mechanical properties, see Strength of materials Chemical properties, see Chemistry Electrical properties, see Electricity Thermal properties, see Thermodynamics Optical properties, see Optics and Photonics Magnetic properties, see Magnetism The properties of a material determine its usability and hence its engineering application.
Their rough endoplasmic reticulum and Golgi apparatus were still not well developed, indicating that despite the change in shape, the fibroblasts still remained mostly in a resting phase. Few newly released materials were seen adjacent to the fibroblasts. The ground substance content in the infant Reinke's space seemed to decrease over time, as the fibrous component content increased, thus slowly changing the vocal fold structure.
Sources: en.wikipedia.org
== 1980s == Though contacts were restricted after the Gleneagles Agreement in 1977, there were controversial tours in 1980 by the British Lions and by France, in 1981 by Ireland, and in 1984 by England. In 1986, though a Lions tour was cancelled, South Africans played in all-star matches in Cardiff and in London marking the IRB centenary. South Africa was excluded from the first two Rugby World Cups, in 1987 and 1991. In 1982 the political relationship between Australia and Argentina was also damaged due to the Falklands War. The Soviet Union supposedly turned down its invitation to the 1987 Rugby World Cup, because of its distaste for the apartheid regime of South Africa. However, South Africa was not invited in the end. While the Great Soviet Encyclopedia states that rugby is popular in Great Britain, New Zealand, France, Romania and Australia, it tellingly makes no mention of South Africa. Chris Thau says that France approached the USSR before 1987 on the issue, and that the Soviets said that they would be happy to participate if South Africa was not invited. In the end, South Africa was not invited, but the USSR did not attend either. It has been said that:
signal transduction The process by which a chemical, electrical, or mechanical signal is converted into a cellular response, or the transmission or propagation of such a signal through a cell as a series of molecular events known as a signaling pathway. For example, the extracellular interaction of a hormone, growth factor, or some other chemical agonist with a specific cell surface receptor can trigger a cascade of sequential biochemical reactions which propagate through the cell membrane and into the cytoplasm, provoking the synthesis of second messengers and leading to amplification of the signal or activation of other pathways. Other modes of transduction involve agonists which diffuse across the membrane freely, eliciting intracellular changes without amplification, or rapid shifts in cell polarity which transmit electrical impulses, such as those that cause the axons of neural cells to release neurotransmitters at synapses.
This success was enough for him to take over the No. 1 ranking in late October. Before the end of the season, Zverev also represented Germany in the Junior Fed Cup, leading them to a fourth-place finish. His last tournament of the year was the Grade A Orange Bowl, where he was defeated by Stefan Kozlov in the semifinals. As the top-ranked junior at the end of the season, he was named the ITF Junior World Champion, becoming the youngest boys' champion since Donald Young in 2005. Zverev played just two tournaments in 2014, both in Australia in January. He won the singles events at both tournaments, the first of which came against Australian Omar Jasika at the Traralgon Junior International. At the Australian Open, he was able to defeat Kozlov, who was seeded second, to finish his junior career with a first major title. Junior Grand Slam results – Singles: Australian Open: W (2014) French Open: F (2013) Wimbledon: 3R (2013) US Open: SF (2013)
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.